Lifecore Biomedical
LFCR
89 hedge funds and large institutions have $306M invested in Lifecore Biomedical in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 29 increasing their positions, 25 reducing their positions, and 9 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 25
0.6% more ownership
Funds ownership: 92.54% → 93.14% (+0.6%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 9
1% less funds holding
Funds holding: 90 → 89 (-1)
17% less capital invested
Capital invested by funds: $367M → $306M (-$60.6M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $11K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Signia Capital Management
Spokane,
Washington
|
+$2.9M |
| 2 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$1.92M |
| 3 |
LCM
Legato Capital Management
San Francisco,
California
|
+$1.23M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$939K |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$645K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
-$1.56M |
| 2 |
AG
Algert Global
San Francisco,
California
|
-$1.48M |
| 3 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$1.39M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.38M |
| 5 |
WC
Walthausen & Co
Malta,
New York
|
-$981K |
LFCR Hedge Fund Activity: Q4 2018 in Review
89 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2018, worth a combined $306M — down 17% from $367M a quarter earlier.
Fund positioning in LFCR was balanced in Q4 2018: 9 funds opened new positions, 9 closed out, 29 added to existing stakes and 25 trimmed.
The largest buyer was Signia Capital Management, opening a new position worth an estimated $2.9M. The largest seller was Foundry Partners, cutting an estimated $1.56M.
- 89 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2018, down from 90 in Q3 2018.
- Funds reported $306M of Lifecore Biomedical stock for Q4 2018, down 17% quarter-over-quarter.
- 9 funds opened new Lifecore Biomedical positions in Q4 2018 and 9 closed out, a net change of 0 holders.
- The largest Lifecore Biomedical buyer in Q4 2018 was Signia Capital Management, an estimated $2.9M added.
- The largest Lifecore Biomedical seller in Q4 2018 was Foundry Partners, an estimated $1.56M sold.
Based on aggregated 13F filings for Q4 2018.